Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Sankyo reports novel hypoglycemic agents

Aug. 30, 1996

No Comments

Positive efficacy/safety profile for maximal-dose sulfonylurea therapy reported

Aug. 30, 1996

No Comments

Beta3-adrenoceptor agonists described by Dainippon

Aug. 30, 1996

No Comments

Cangene and Cheil Jedang sign Leucotropin agreement

Aug. 30, 1996

No Comments

CCK antagonists from Warner-Lambert

Aug. 30, 1996

No Comments

NGD-95-1 demonstrates safety in phase I

Aug. 30, 1996

No Comments

More squalene synthase inhibitors from Pfizer

Aug. 30, 1996

No Comments

Xenical to be marketed in 1997

Aug. 30, 1996

No Comments

SDZ-266806: A novel squalene synthase inhibitor

Aug. 30, 1996

No Comments

Estrogenic compounds from Sankyo

Aug. 30, 1996

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Endocrine/metabolic
RSS

Sankyo reports novel hypoglycemic agents

Positive efficacy/safety profile for maximal-dose sulfonylurea therapy reported

Beta3-adrenoceptor agonists described by Dainippon

Cangene and Cheil Jedang sign Leucotropin agreement

CCK antagonists from Warner-Lambert

NGD-95-1 demonstrates safety in phase I

More squalene synthase inhibitors from Pfizer

Xenical to be marketed in 1997

SDZ-266806: A novel squalene synthase inhibitor

Estrogenic compounds from Sankyo

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership

Endocrine/metabolic RSS

Endocrine/metabolic
RSS